可注射光交联球体凝封装向酸修饰工程外体,用于骨关节炎治疗
Junlai Wan1,2, Zhiyi He1, Renpeng Peng1
1Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095#, Jie-Fang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China.
Journal of nanobiotechnology
|August 22, 2023
概括
在水凝中封装的工程外体对骨关节炎治疗有希望. 在临床前模型中,这些向外体改善了药物输送,减少了炎症,并促进了软骨修复.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 药物运输 药物运输 药物运输
背景情况:
- 骨关节炎 (OA) 是一种普遍存在的退行性关节疾病,有效治疗方法有限.
- 介质细胞 stromal 细胞衍生的外体 (Exo) 显示治疗潜力,但遭受快速清除和不良保留.
- 需要新的策略来提高OA治疗的外体疗效.
研究的目的:
- 为骨关节炎治疗开发具有改进向和保留能力的工程外体.
- 为了研究LRRK2-IN-1装载的,在水凝系统中封装的改异体的治疗疗效.
主要方法:
- 制造光交叉连接球形凝甲基基凝 (GelMA) 封装软骨亲和力 WYRGRL基改造工程外体 (W-Exo).
- 将LRRK2-IN-1抑制剂加载到W-Exo@GelMA (W-Exo-L@GelMA) 中.
- 在体外评估冠状细胞向,解消/合成调节和抗炎作用.
- 在OA小鼠模型中对保留,抗OA活性和软骨修复的体内评估.
- 在培养的人类OA软骨中进行验证.
主要成果:
- W-Exo-L@GelMA表现出有效的冠状细胞向和调节的冠状细胞代谢,通过抑制催化和促进催化.
- 工程外体显著抑制了OA相关的炎症和免疫基因表达,扭转了IL-1β诱导的转录基因变化.
- 加强W-Exo-L@GelMA的关节保留导致了优越的抗骨关节炎活性和软骨修复 in vivo.
- 人类OA软骨扩展剂的治疗效果得到证实.
结论:
- 摄影交叉连接凝封装,改造的工程外体代表了对骨关节炎的有希望的治疗策略.
- 通过多种策略对外体进行工程,显著提高了它们的向能力和对软骨特异性药物递送的保留能力.
- 这种方法为骨关节炎治疗提供了一种新且有效的途径,解决了当前基于外体细胞的治疗方法的关键局限性.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


